Your Location：
Home >
Browse articles >
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
- Military Medical Research Vol. 11, Issue 1, Pages: 98-114(2024)
DOI： 10.1186/s40779-023-00455-x
Scan QR Code
Full Text(HTML)
Figs( 3 ) Tabs( 0 )
References
Publication Info
Metrics
43
Views
21
Downloads
0
CSCD
Alert me when the article has been cited
Submit
Tools
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Related Articles
Bioengineered exosomal-membrane-camouflaged abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine
Activated Drp1 regulates p62-mediated autophagic flux and aggravates inflammation in cerebral ischemia-reperfusion via the ROS-RIP1/RIP3-exosome axis
Activation of systemic immune effectors and induction of cytokine production by direct intratumoral injection of IL-2 DNA liposome
Bridging the lung cancer screening eligibility gap: evaluation of guideline applicability in asymptomatic patients
From RCT to mechanistic study: ATRA reverses myofibroblast activation by reprogramming glucose metabolism via HIC1 and PCK1/2 to attenuate hypertrophic scar formation
Related Author
Guang-Long Ma
Ana Cláudia Paiva-Santos
Miguel Pereira-Silva
Joana Lopes
Daniela Lopes
Diana Peixoto
Navid Rabiee
Omid Moradi
Related Institution
Centre for Cancer Immunology, Faculty of Medicine, University of Southampton
School of Engineering, Institute for Bioengineering, the University of Edinburgh
Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University Shanghai Medical College
Integrated Composites Laboratory (ICL), Department of Mechanical and Construction Engineering, Northumbria University
Department of Chemistry, Shahr-e-Qods Branch, Islamic Azad University
